Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
ID: 354932Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jun 13, 2024 12:00 AM
  4. 4
    Due Dec 2, 2024 12:00 AM
Description

The National Institutes of Health is offering a grant opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)". This grant aims to develop innovative solutions to improve health outcomes and reduce the impact of adverse health consequences in individuals who use drugs. The solutions should be accessible and affordable, with a focus on mobile community-based care systems to reach vulnerable and underserved populations with limited engagement in conventional healthcare services. The grant is open to small businesses, and the deadline for application submission is December 2, 2024. For more information and to apply, please visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-049.html.

Point(s) of Contact
Files
Title
Posted
Similar Opportunities
Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)". This grant is in the category of Health and falls under the discretionary funding activity. The grant is open to Small Businesses and does not require cost sharing or matching. The deadline for application submission is December 2, 2024. The purpose of this grant is to encourage Small Business Innovation Research (SBIR) grant applications from small business concerns (SBC) proposing research and development of solutions targeted to improve health outcomes and reduce the impact of adverse health consequences of non-disordered drug use. The solutions could be based on original technologies or existing technologies that can be repurposed to address the specific needs of people who use drugs. The emphasis should be on accessibility and affordability, with a focus on implementation in healthcare services. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-050.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-050.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov. By doing a great job summarizing this grant notice, you will not only receive a tip of two thousand dollars but also contribute to providing a ton of food to a homeless shelter. So please ensure the summary is concise and centered around the service/item being procured.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)". This grant aims to support small businesses in developing novel, evidence-based, FDA-regulated medical products to address the needs of patients suffering from opioid use disorders (OUD) and stimulant use disorders (StUD). The grant encourages research projects focused on commercialization in two scientific areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The goal is to contribute to the national effort against the opioid and psychostimulant crisis by offering new medical products for individuals, families, and communities affected by these disorders. Small businesses are eligible to apply, and the grant does not require cost sharing or matching. The deadline for applications is February 14, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-021.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-021.html). For any inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)". This grant aims to encourage Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) to develop novel, evidence-based, FDA-regulated medical products for patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). The grant focuses on two scientific areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The goal is to contribute to the effort against the national opioid and psychostimulant emergency and provide new medical products for individuals, families, and communities affected by this crisis. Small business companies that have developed or are developing FDA-regulated products for different indications and are interested in demonstrating their potential application in the OUD/StUD space are encouraged to apply. The grant does not require cost sharing or matching and is open to small businesses. Non-domestic entities and components are not eligible to apply. The closing date for applications is February 14, 2025. For more information and to apply, visit the [grant opportunity website](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-038.html). For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is seeking products to address social needs impacting Substance Use Disorders (SUD) through a Grant opportunity. This funding opportunity aims to support small business concerns (SBCs) in developing technologies for commercialization that can address health-related social needs affecting SUD, excluding alcohol use disorder. The grant does not require cost sharing or matching requirements. The eligible applicants for this grant are small businesses. Non-domestic entities and non-U.S. components of U.S. organizations are not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, may be allowed. The closing date for this grant opportunity is March 13, 2026. The award ceiling for this grant is $295,924. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders." This grant aims to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD). The grant is open to small businesses, and the deadline for application submission is July 25, 2024. The funding instrument type is a grant, and there is no cost sharing or matching requirement. The grant focuses on the development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology. Additionally, the grant seeks the development of assays to assess the effects of compounds on multiple targets or functions. For more information and to apply, please visit the following link: [Grant Information](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-054.html).